1992 Fiscal Year Final Research Report Summary
Study on the extrinsic blood coagulation
| Project/Area Number |
03680151
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
物質生物化学
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
MIYATA Toshiyuki Natl. Cardiovascular Ctr. Ras. Inst. Lab. Thromb. Res., Senis staff, 脈管生理部, 室長 (90183970)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWABATA Shunichiro Kyushu Univ., Science., Research Assistant, 理学部, 助手 (90183037)
|
|---|
| Project Period (FY) |
1991 – 1992
|
| Keywords | Blood Coagulation / Tissue factor / Thrombosis / Recombinant Protein |
|---|
| Research Abstract |
The extracellular domain of human tissue factor (TF, amino acids 1-217) was expressed in Saccharomyces cerevisiae, using the inducible yeast acid phosphatase promoter and the yeast invertase signal sequence to direct its secretion into the culture broth. Two active soluble forms sTF_<alpha> (high molecular weight form) and sTFbeta (low molecular weight form) were purified, the yield being approximately 10 and 1 mg/liter of culture supernatant, respectively. sTF_<alpha> had an apparent molecular mass of 150 kDa on SDS-polyacrylamide gel electrophoresis and contained more than 200 residues of mannose/mol of protein. sTFbeta had an apparent molecular mass of 37 kDa and contained 22 residues of mannose/mol of protein. N-Glycosidase F treatments of both rTFs reduced the apparent molecular mass to 35 kDa. The amino-terminal sequences and amino acid compositions of sTF_<alpha> and sTFbeta were consistent with those deduced from the cDNA sequence, thereby indicating that the difference in molecular mass is caused by heterogeneity of oligosaccharide structures. Of these recombinant TFs, sTFbeta enhanced factor VIIa-amidolytic activity 40-fold toward the chromogenic substrate and 147-fold toward the fluorogenic substrate, affecting mainly the kcat value. The enhancement was comparable with that of TF purified from human placenta. The TF-mediated enhancement of factor VIIa-amidolytic activity was inhibited by heparin-activated antithrombin III, forming a high molecular weight complex. As treatment of sTFbeta with denaturants such as guanidine hydrochloride or urea led to a biphasic loss of the activity, the extracellular domain of TF probably consists of two discrete domains. This expression system provides a significant amount of the extracellular domain of TF so that studies of interactions with factor VII are feasible.
|
